PMID- 20853144
OWN - NLM
STAT- MEDLINE
DCOM- 20110523
LR  - 20211020
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 38
IP  - 3
DP  - 2011 Mar
TI  - The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE 
      activity and response to ACE inhibitor and angiotensin II receptor antagonist 
      drugs in Iranians type II diabetic patients with microalbuminuria.
PG  - 2117-23
LID - 10.1007/s11033-010-0338-1 [doi]
AB  - The aim of present study was to determine if factor V Leiden (FVL) mutation and 
      angiotensin converting enzyme insertion/deletion (ACE I/D) polymorphism are 
      associated with diabetic nephropathy (DN) among Kurdish population from Western 
      Iran. This case-control study comprised 144 unrelated adult type 2 diabetic 
      mellitus patients (T2DM) including 72 patients with microalbuminuria and 72 age 
      and sex matched patients without nephropathy. The ACE I/D polymorphism and FVL 
      mutation were detected by polymerase chain reaction (PCR) and PCR-RFLP, 
      respectively. The frequency of FVL G1691A and ACE D allele in T2DM patients with 
      microalbuminuria were 1.6 and 57%, respectively and in normoalbuminuric T2DM 
      patients were 4.9 and 58.3%, respectively (P > 0.05). ACE genotypes affected on 
      serum ACE activity and a better response to ACE inhibitor therapy (captopril) 
      compared to angiotensin II receptor antagonist (losartan) was obtained with 
      significant reduction of ACE activity in diabetic patients without nephropathy 
      carrying DD genotype. However, the beneficial effect of losartan therapy was 
      observed in microalbuminuric patients with II genotype compared to ID and DD 
      genotypes.
FAU - Rahimi, Zohreh
AU  - Rahimi Z
AD  - The Rhazes Center for Research in Family Health and Sexual Medicine, Kermanshah 
      University of Medical Sciences, Kermanshah, Iran. zrahimi@kums.ac.ir
FAU - Felehgari, Vahid
AU  - Felehgari V
FAU - Rahimi, Mehrali
AU  - Rahimi M
FAU - Mozafari, Hadi
AU  - Mozafari H
FAU - Yari, Kheirollah
AU  - Yari K
FAU - Vaisi-Raygani, Asad
AU  - Vaisi-Raygani A
FAU - Rezaei, Mansour
AU  - Rezaei M
FAU - Malek-Khosravi, Shohreh
AU  - Malek-Khosravi S
FAU - Khazaie, Habibolah
AU  - Khazaie H
LA  - eng
PT  - Journal Article
DEP - 20100919
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (factor V Leiden)
RN  - 9001-24-5 (Factor V)
RN  - 9G64RSX1XD (Captopril)
RN  - EC 3.4.15.1 (ACE protein, human)
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Albuminuria/*complications/genetics
MH  - Alleles
MH  - Angiotensin Receptor Antagonists/*therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Captopril/therapeutic use
MH  - Diabetes Mellitus, Type 2/complications/drug therapy/enzymology/*genetics
MH  - Diabetic Nephropathies/complications/drug therapy/enzymology/genetics
MH  - Factor V/*genetics
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Iran
MH  - Losartan/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Peptidyl-Dipeptidase A/*blood/*genetics
MH  - Polymorphism, Genetic
MH  - Treatment Outcome
EDAT- 2010/09/21 06:00
MHDA- 2011/05/24 06:00
CRDT- 2010/09/21 06:00
PHST- 2010/01/31 00:00 [received]
PHST- 2010/09/04 00:00 [accepted]
PHST- 2010/09/21 06:00 [entrez]
PHST- 2010/09/21 06:00 [pubmed]
PHST- 2011/05/24 06:00 [medline]
AID - 10.1007/s11033-010-0338-1 [doi]
PST - ppublish
SO  - Mol Biol Rep. 2011 Mar;38(3):2117-23. doi: 10.1007/s11033-010-0338-1. Epub 2010 
      Sep 19.